Dermata Therapeutics, Inc. (DRMA): Price and Financial Metrics

Dermata Therapeutics, Inc. (DRMA): $0.70

0.01 (+1.38%)

POWR Rating

Component Grades













Add DRMA to Watchlist
Sign Up

Industry: Biotech



in industry

DRMA Stock Price Chart Interactive Chart >

Price chart for DRMA

DRMA Price/Volume Stats

Current price $0.70 52-week high $6.95
Prev. close $0.69 52-week low $0.62
Day low $0.65 Volume 21,900
Day high $0.73 Avg. volume 412,280
50-day MA $1.07 Dividend yield N/A
200-day MA $0.00 Market Cap 6.46M

Dermata Therapeutics, Inc. (DRMA) Company Bio

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.

DRMA Latest News Stream

Event/Time News Detail
Loading, please wait...

DRMA Latest Social Stream

Loading social stream, please wait...

View Full DRMA Social Stream

Latest DRMA News From Around the Web

Below are the latest news stories about Dermata Therapeutics Inc that investors may wish to consider to help them evaluate DRMA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | February 10, 2022

Dermata, Innoviva top healthcare gainers; while InfuSystem, Seagen lead losers pack

Gainers: Dermata Therapeutics DRMA +35%. Innoviva (INVA) +11%. Mainz Biomed (MYNZ) +9%. Regional Health Properties RHE +9%. Envista Holdings (NVST) +8%.Losers: InfuSystem

Seeking Alpha | February 10, 2022

Thinking about buying stock in Dermata Therapeutics, Ironnet, Preferred Apartment Communities, Mattel, or Viking Therapeutics?

NEW YORK , Feb. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRMA, IRNT, APTS, MAT, and VKTX. Full story available on

Benzinga | February 10, 2022

IceCure Medical, Atossa top healthcare gainers; Dermata, Statera among losers

IceCure Medical ICCM +16%. Atossa Therapeutics (ATOS) +15%. Dermata Therapeutics (DRMA) -31%. Statera Biopharma STAB -26%.

Seeking Alpha | February 7, 2022

Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

Dermata Therapeutics Inc (NASDAQ: DRMA ) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company … Full story available on

Benzinga | February 7, 2022

Read More 'DRMA' Stories Here

DRMA Price Returns

1-mo -44.88%
3-mo N/A
6-mo -69.96%
1-year N/A
3-year N/A
5-year N/A
YTD -59.77%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6864 seconds.